Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?
Clinical Gastroenterology and Hepatology · 2024
DOI: 10.1016/j.cgh.2023.05.007 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Munique Kurtz De Mello und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Vale do Itajaí, Itajaí, Brazil. Hauptthemen laut MEDLINE: Drug Monitoring, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Vale do Itajaí, Itajaí, Brazil.
- Division of Gastroenterology, Pontifical Catholic University of Paraná (PUCPR), Curitiba, Brazil; Santa Cruz Hospital, Curitiba, Brazil.
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
De Mello, M. K., Freitas Queiroz, N. S., & Papamichael, K. (2024). Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.05.007
Vancouver
De Mello MK, Freitas Queiroz NS, Papamichael K. Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.05.007
BibTeX
@article{DeMello2024,
author = {De Mello, Munique Kurtz and Freitas Queiroz, Natália Sousa and Papamichael, Konstantinos},
title = {Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
doi = {10.1016/j.cgh.2023.05.007}
}
EUVIMED